Yulin First People's Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Stroke3 trials
• Aortic stenosis2 trials
• Coronary artery disease2 trials
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Thalassaemia1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Not yet recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
• Second Affiliated Hospital, Zhejiang University, School of Medicine2 trials
• Beijing Tiantan Hospital1 trial
• Boehringer Ingelheim1 trial
• First Affiliated Hospital of Guangxi Medical University1 trial
• and 3 more

Running trials

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients

  NCT07338344· Phase 2· Rongrong Liu· Source

  Contact: Jun Wan

• Recruiting

  D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

  NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

  Contact: Haizhen Yi, Master

• Active, not recruiting

  CRUSTAL Study in China

  NCT05828186· First Affiliated Hospital of Guangxi Medical University· Source

• Active, not recruiting

  Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)

  NCT05511792· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Active, not recruiting

  To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

  NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

  NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source

  Contact: Ping Li

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Lung cancer1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Completed

  Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

  NCT06316570· Phase 3· Beijing Tiantan Hospital· Source

• Completed

  Comparison of a Single Versus Double Perclose Technique for TAVR

  NCT06173115· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Completed

  Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke

  NCT05631847· Sichuan Academy of Medical Sciences· Source